Latest News
Lynk Pharmaceuticals completes patient enrolment for zemprocitinib Phase III clinical trial in ankylosing spondylitis
15 July 2026 - Lynk Pharmaceuticals Co Ltd, a clinical-stage drug development company focused on immune and inflammatory diseases, announced on Tuesday the completion of patient enrolment in the Phase III clinical trial evaluating its core product ze...
Kelun-Biotech's Phase III study of sac-TMT in combination with pembrolizumab meets primary endpoint
15 July 2026 - Chinese pharmaceutical company Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HK:6990) announced on Tuesday that a Phase III clinical study (OptiTROP-Lung06) of its trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug con...
AstraZeneca signs global licence deal with Dizal for lung cancer drug Zegfrovy
14 July 2026 - Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) announced on Tuesday that it has agreed an exclusive worldwide licence with China's Dizal Pharmaceutical Co., Ltd (SSE: 688192) for Zegfrovy (sunvozertinib)...
Summit Therapeutics sells Phase III antibiotic asset ridinilazole to Biossil
14 July 2026 - Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) on Tuesday announced an agreement to sell ridinilazole, an investigational Phase III precision antibiotic, to Toronto-based Biossil Inc, an AI-native biopharma co...
European Commission approves Erbitux combination for first-line BRAF V600E-mutant mCRC
14 July 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Tuesday that the European Commission has approved an updated label for Erbitux (cetuximab), allowing its use in combination w...